Momenta Pharmaceuticals (MNTA) Well Positioned Ahead of M254 Phase I/II Part B Update - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $45.00 price target on Momenta Pharmaceuticals (NASDAQ: MNTA) citing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
